

[Click here to view linked References](#)

1 **Non-invasive imaging reveals conditions that impact distribution and persistence of cells**
2 **after *in vivo* administration**

3
4
5
6
7
8 **Authors:** Lauren Scarfe^{1,2,§}, Arthur Taylor^{1,2,§}, Jack Sharkey^{1,2,§}, Rachel Harwood^{1,2}, Michael
9 Barrow⁴, Joan Comenge⁵, Lydia Beeken¹, Cai Astley¹, Ilaria Santeramo^{1,2}, Claire Hutchinson³,
10 Lorenzo Ressel⁶, Jon Smythe⁷, Eric Austin⁷, Raphael Levy⁵, Matthew J. Rosseinsky⁴, Dave J.
11 Adams⁸, Harish Poptani^{1,2}, Brian K. Park³, Patricia Murray^{1,2,*}, Bettina Wilm^{1,2,*}

12
13
14
15
16
17
18
19
20
21 **Affiliation:**

22
23 ¹ Department of Cellular and Molecular Physiology, ² Centre for Preclinical Imaging, ³
24 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, ⁴
25 Department of Chemistry, ⁵ Institute of Integrative Biology, ⁶ Department of Veterinary
26 Pathology and Public Health, Institute of Veterinary Science, University of Liverpool,
27 Liverpool, UK, ⁷ NHS Blood and Transplant, Oxford, UK, ⁸ School of Chemistry, College of
28 Science and Engineering, University of Glasgow, Glasgow, UK,
29
30
31
32

33
34
35
36
37
38 [§] Authors contributed equally

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
*** Joint senior/corresponding authors**

e-mail addresses:

66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1 M.J.R.: rossein@liverpool.ac.uk; D.J.A.: Dave.Adams@glasgow.ac.uk; H.P.:

2 Harish.Poptani@liverpool.ac.uk; B.K.P.: bkpark@liverpool.ac.uk; P.M.:

3 P.A.Murray@liverpool.ac.uk; B.W.: bwilm@liverpool.ac.uk

4 **Correspondence information for corresponding authors:**

5 Patricia Murray, PhD, Department of Cellular and Molecular Physiology, Institute of

6 Translational Medicine, University of Liverpool, Liverpool L69 3BX, UK; Tel: +44-151-

7 7945450, email: p.a.murray@liverpool.ac.uk

8 Bettina Wilm, PhD, Department of Cellular and Molecular Physiology, Institute of

9 Translational Medicine, University of Liverpool, Liverpool L69 3BX, UK; Tel: +44-151-

10 7954988, email: b.wilm@liverpool.ac.uk

11

12

13

14

15

16

17

18

19

20

21

22

1 **Abstract**

2 **Background:** Cell-based regenerative medicine therapies are now frequently tested in
3 clinical trials. In many conditions, cell therapies are administered systemically, but there is
4 little understanding of their fate, and adverse events are often under-reported. Currently, it
5 is only possible to assess safety and fate of cell therapies in preclinical studies, specifically by
6 monitoring animals longitudinally using multimodal imaging approaches. Here, using a suite
7 of *in vivo* imaging modalities to explore the fate of a range of human and murine cells, we
8 investigate how route of administration, cell type and host immune status affect the fate of
9 administered cells. **Methods:** We applied a unique imaging platform combining
10 bioluminescence, optoacoustic and magnetic resonance imaging modalities to assess the
11 safety of different human and murine cell types by following their biodistribution and
12 persistence in mice following administration into the venous or arterial system. **Results:**
13 Longitudinal imaging analyses (i) suggested that the intra-arterial route may be more
14 hazardous than intravenous administration for certain cell types; (ii) revealed that the
15 potential of a mouse mesenchymal stem/stromal cell (MSC) line to form tumours, depended
16 on administration route and mouse strain; and (iii) indicated that clinically tested human
17 umbilical cord (hUC)-derived MSCs can transiently and unexpectedly proliferate when
18 administered intravenously to mice. **Conclusions:** In order to perform an adequate safety
19 assessment of potential cell-based therapies, a thorough understanding of cell
20 biodistribution and fate post administration is required. The non-invasive imaging platform
21 used here can expose not only the general organ distribution of these therapies, but also a
22 detailed view of their presence within different organs and, importantly, tumourigenic
23 potential. Our observation that the hUC-MSCs but not the human bone marrow (hBM)-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 derived MSCs persisted for a period in some animals, suggests that therapies with these cells

2 should proceed with caution.

3

4 Keywords: cell therapies, mesenchymal stem/stromal cells, safety, preclinical models, cell

5 tracking, multi-modal imaging.

6

7

1 Background

2 In recent years, biomedical and translational research has focussed on exploring the
3 potential of regenerative medicine therapies (RMTs) to treat a vast number of diseases[1]. A
4 primary safety concern of RMTs, especially if based on stem cells, is their potential to form
5 tumours, due to their proliferative and multi-potential differentiation characteristics[2].
6 Mesenchymal stem/stromal cells (MSCs) isolated from bone marrow, adipose tissue or
7 umbilical cord are being tested in clinical trials for a range of conditions, but in many cases,
8 preclinical safety data are not available, and the authors fail to report whether the cells
9 cause any adverse effects. Bone marrow-derived MSCs have been used for many years and
10 appear safe[3], but a review of adipose-derived MSCs concluded that while adverse events
11 are rare, they nevertheless do occur, and are likely to be related to underlying health
12 conditions of the patients or administration route[4]. Human umbilical cord-derived (hUC)-
13 MSCs have only recently been introduced in clinical trials, with more than 50% of these
14 initiated within the last 3 years (a summary of registered trials is presented in Additional File
15 1). hUC-MSCs are less immunogenic than other types of MSCs, which contributes to their
16 attraction as clinical RMTs. However, because of their low immunogenicity in combination
17 with higher proliferative behaviour, these cells may also pose a greater potential risk[5], yet
18 until now, their safety profile has not been robustly assessed. The importance of preclinical
19 safety testing is highlighted by a recent report where a tumour developed in a patient's
20 spinal cord following intrathecal administration of stem cells[6].

21

22 Assessing the safety of cell therapies by tracking their distribution and fate over time after
23 administration can be achieved in preclinical models. Many animal studies use lipophilic
24 membrane dyes, such as PKH26 or CM-Dil, to label the cells, which requires culling of

1 animals at various time points and histological analysis[7-11]. The key flaws of this approach
2 are (1) the detection of false positive cells because lipophilic dyes have the potential to
3 transfer to host cells[12]; (2) very large animal numbers, infringing on the principles of the
4 3Rs (Replacement, Reduction, Refinement); and (3) the failure to longitudinally monitor the
5 cell fate in each individual animal over time. By contrast, non-invasive imaging technologies
6 have opened up exciting new possibilities for preclinical assessment of the safety of cell
7 therapies by allowing longitudinal *in vivo* cell tracking to monitor cell biodistribution and
8 persistence. Preclinical imaging technologies for cell tracking, some of which have clinical
9 relevance, include magnetic resonance imaging (MRI) to detect cells labelled with
10 superparamagnetic iron oxide nanoparticles (SPIONs), multispectral optoacoustic
11 tomography (MSOT) to detect cells labelled with gold nanorods (GNRs) or near-infrared red
12 fluorescent protein[13-17], and bioluminescence imaging (BLI) for the detection of cells
13 expressing the genetic reporter, firefly luciferase[18-20]. Genetic reporters are particularly
14 advantageous because signals are only generated from living cells, thus allowing the
15 monitoring of cell proliferation and tumour growth, and avoiding problems based on
16 nanoparticle dissociation from cells, which can lead to false positive signals. However, the
17 spatial resolution of BLI is poor, making it difficult to precisely locate the cells[18]. By
18 contrast, both preclinical MSOT and MRI have much higher spatial resolution (150 μm and
19 50 μm , respectively), providing details of the inter- and intra-organ distribution of
20 administered cells. Moreover, as MRI is routinely used in the clinic, it provides a bridge for
21 preclinical and clinical studies.

22 An advanced approach to longitudinal *in vivo* cell tracking is the use of multi-modal imaging
23 strategies that combine cell labels and reporters, including dual-labelling with both the
24 luciferase reporter gene for BLI, and either gold nanorods (GNRs) for photoacoustic

1 imaging[21-24], or superparamagnetic iron oxide nanoparticles (SPIONs) for MRI[25-28]. Such
2 multi-modal imaging approaches benefit from the sensitivity of the luciferase-based signal
3 conferred by living cells, in combination with the high resolution of MRI and photoacoustic
4 imaging systems to detect the nanoparticles inside organs, allowing a comprehensive
5 longitudinal analysis of cell fate and safety risks.

6
7 The most common way to administer cells systemically in small animals is via the intravenous
8 (IV) route through the tail vein [29], delivering cells directly to the lungs where they are
9 sequestered as a consequence of the pulmonary first-pass effect[30-35]. Previous reports
10 have suggested that IV administered cells labelled with lipophilic dyes bypass the lungs, but
11 this is likely due to false positive staining. For example, in renal regenerative studies, PKH26
12 dye-labelled IV administered cells have been reported to engraft in injured kidneys and
13 replace damaged renal cells [9-11, 36], but a more recent study using this lipophilic dye in
14 combination with GFP expression shows that while the dye can sometimes be detected in the
15 kidneys, the cells remain trapped in the lungs[32]. These recent findings are corroborated by
16 *in vivo* cell tracking studies which show that after IV injection, transplanted cells
17 predominantly accumulate in the lungs[19, 33, 34], fail to integrate or differentiate into tissue-
18 specific cell types and disappear within 7 days [19, 20, 37].

19 Although the IV route is also frequently used in clinical trials, administration via the arterial
20 circulation is not uncommon. For instance, clinical trials testing the potential of cell therapies
21 to treat myocardial infarction administer cells into the coronary arteries or left cardiac
22 ventricle[24, 38], while in patients with peripheral artery disease or stroke, intra-arterial
23 injection via the femoral or carotid artery, respectively, is frequently employed[39]. Intra-
24 arterial administration will also lead to systemic distribution to other organs, including the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 brain, and cells passing through the blood-brain barrier could pose an important safety
2 concern. However, a detailed analysis of cell fate after intra-arterial cell administration has
3 so far not been reported [4].

4 Here, we have implemented a multi-modal imaging approach comprising BLI, MSOT and
5 MRI, to assess biodistribution and fate of different cell types following venous and arterial
6 administration in healthy mice. Some of these cell types are currently being used in clinical
7 trials, including hUC-MSCs (Additional File 1), hBM-MSCs[40], kidney-derived cells[41] and
8 macrophages[42]. We show that our multi-modal imaging approach allows us to determine
9 the immediate distribution of the cells with respect to the route of administration, and to
10 assess the long-term fate of mouse and human MSCs, and their propensity to form tumours.
11 Our findings demonstrate that the multi-modal imaging platform allowing longitudinal cell
12 tracking is an important tool to identify safety concerns of cells used in clinical trials.

1 **Methods**

2 Animals

3 Mice (Charles River, UK) were housed in individually ventilated cages under a 12 hour
4 light/dark cycle, with *ad libitum* access to standard food and water. All animal experiments
5 were performed under a licence granted under the UK Animals (Scientific Procedures) Act
6 1986 and were approved by the University of Liverpool ethics committee. Experiments are
7 reported in line with the ARRIVE guidelines. Tumour formation was closely monitored and
8 the tumour burden was not allowed to exceed the recommended size[43].

9
10 Cell Preparation

11 Mouse kidney-derived stem cells (mKSCs)[44], the D1 mouse MSC (mMSC) line (D1 ORL UVA
12 [D1](ATCC® CRL-12424™)), primary human umbilical cord-derived MSCs (hUC-MSCs;
13 collected from consenting donors and produced identically to those already being used in
14 clinical trials by NHS Blood and Transplant (NHSBT)), primary human bone marrow-derived
15 MSCs (hBM-MSCs; Lonza PT-2501), human kidney cells (hKCs; kidneys deemed unsuitable for
16 transplantation via UK NHSBT[32]) and RAW264.7 macrophages (European Collection of
17 Authenticated Cell Cultures 91062702) were cultured at 37°C under a humidified
18 atmosphere with 5% CO₂ (culture media are described in Additional File 2). Primary human
19 cells were used up to passage 8, whereas mouse lines were cultured up to passage 25.
20 For detection by BLI, cells were transduced with a lentiviral vector encoding either firefly
21 luciferase (Luc) or a bicistronic construct of Luc and ZsGreen, all under control of the
22 constitutive promoter EF1a. The vector plasmids were a gift from Bryan Welm (Addgene
23 plasmids # 21375 and 39196) and the production of viral particles and cell transduction was
24 carried out as previously described[45, 46]. The mKSCs were infected with a multiplicity of

1 infection (MOI) of 10, whereas all other cells were infected with an MOI of 5. At least 90% of
2 the cell populations expressed the vector after transduction, except for macrophages, which
3 did not tolerate polybrene and thus displayed a reduced infection efficiency. Cell sorting
4 based on ZsGreen fluorescence obtained a macrophage population that was 100% positive
5 for the luciferase construct. Cells for karyotyping were treated with colcemid (0.1 µg/mL)
6 followed by a hypotonic treatment and fixation in Carnoy's fixative. Chromosome analyses
7 were carried out by cytogenetics specialists (CellGS, Cambridge, UK).

8 Average cell diameter was estimated by measuring the volume of a cell pellet in a packed
9 cell volume (PCV) tube according to the manufacturer's instructions (Techno Plastic
10 Products, Switzerland). The cell diameter was calculated using the formula:

$$\phi_{cell} = 2 \times \sqrt[3]{\frac{3V/c}{4\pi}}$$

13 where V corresponds to the pellet volume, and c to the number of cells in the pellet.

14 For MR tracking, cells were labelled with diethylaminoethyl-dextran coated SPIONs
15 synthesised in house as previously described[25, 26]. SPIONs were added to the culture
16 medium at a concentration of 25 µg[Fe]/mL 24h prior to the experiment, after which cells
17 were washed to remove excess particles and harvested for administration as described
18 below. This resulted in an iron content of ~ 6 pg[Fe]/cell.

19 GNRs were synthesised using a protocol first reported by El-Sayed's group[47] and coated
20 with silica as described by Comenge *et al.*[23]. Macrophages were labelled for 24h with
21 GNRs at a final concentration of 10 pM before harvesting for cell injection. Neither of the
22 labelling approaches (SPIONs/GNRs) caused any reduction in cell viability.

1 Cell administration

2 Cells were trypsinised, pelleted, resuspended in ice-cold phosphate buffered saline (PBS) and
3 kept on ice until injection. 100µl cell suspension was administered to mice via intravenous
4 (IV) or ultrasound-guided intracardiac (IC) injection. A description and comments on this
5 method of administration is provided in Additional File 3. **Tolerance of dosing of cells was**
6 **adjusted in separate experiments.**

8 Bioluminescence imaging

9 Short-term study: ZsGreen⁺/Luc⁺ mMSCs, mKSCs, hKCs, macrophages or Luc⁺ hUC-MSCs
10 were administered IV or IC to BALB/c mice. Long-term study: ZsGreen⁺/Luc⁺ mMSCs or Luc⁺
11 hUC-MSCs were administered by IV or IC to BALB/c (severe combined immunodeficient)
12 SCID mice (see Table 1 for route, cell dose and number of animals in each experiment). The
13 *in vivo* biodistribution of cells was monitored by BLI immediately after cell administration,
14 and at multiple time points up to 30 days. Mice were administered 150 mg/kg body weight
15 luciferin (Promega, UK) subcutaneously, and imaged 15 min later in a bioluminescence
16 imager (IVIS Spectrum, Perkin Elmer, UK). Imaging data were normalised to the acquisition
17 conditions and expressed as radiance (photons/second/cm²/steradian (p/s/cm²/sr)), and the
18 colour scale was adjusted according to the strength of signal detected. Because IV injections
19 into the tail can lead to a small fraction of cells remaining in or around the injection site,
20 causing strong signal intensities, the tails of animals that received cells via this route were
21 covered prior to data acquisition. At the respective study end points, mice were culled and
22 organs with any visibly identifiable tumours imaged *ex vivo* by BLI. Kidneys were cut
23 coronally for *ex vivo* imaging, and all other organs were imaged whole. Bioluminescence
24 signals of whole live mice or individual organs *ex vivo* were quantified by drawing regions of

1 interest (ROIs) from which the total flux (photons/second) was obtained. The relative signal
2 intensity from each organ was calculated as a percentage of the signal intensity from all
3 organs. For *ex vivo* kidney imaging, the ROI was drawn around all four kidney halves and a
4 single value for total bioluminescence signal was recorded.

6 Multispectral Optoacoustic Tomography (MSOT)

7 MSOT was carried out using the inVision 256-TF MSOT imaging system (iThera Medical,
8 Munich). Images were recorded at the following wavelengths: every 10 nm from 660 nm and
9 760nm, and every 20 nm from 780 nm and 900 nm, at a rate of 10 frames per second and
10 averaging 10 consecutive frames. All mice were allowed to equilibrate in the imaging system
11 for 15 minutes prior to recording data. For monitoring of the biodistribution of macrophages
12 after IV administration, a 15 mm section of the abdomen to include the liver, kidneys and
13 spleen of the mice was imaged repeatedly for a total of 4.5 hours; 30 minutes into the
14 imaging the mice received the macrophages via a tail vein catheter. For the IC imaging a 15
15 mm section of the abdomen was imaged once, followed by an ultrasound (Prospect 2.0, S-
16 Sharp, Taipei city) guided injection of 10^7 macrophages into the left ventricle of the heart.
17 Mice were then returned to the photoacoustic imaging system for imaging as previously
18 described. Data was reconstructed and multispectral processing was performed to resolve
19 signals in the liver, kidney and spleen for GNRs. Regions of interest were drawn around the
20 liver, right kidney and spleen (an example is shown in Additional File 4) to generate mean
21 pixel intensity data.

23 MR imaging

1 ZsGreen⁺/Luc⁺/SPION⁺ mMSCs (10⁶) were administered to BALB/c mice IV (*n* = 2) or IC (*n* = 2
2 for short-term analysis; *n* = 5 for longitudinal tracking). The biodistribution of cells in the
3 brain and kidney was imaged with a Bruker Avance III spectrometer interfaced to a 9.4T
4 magnet system (Bruker Biospec 90/20 USR) using a Fast Low-Angle Shot (FLASH) T₂*
5 weighted sequence at baseline and up to 2 days post administration. T₂* relaxation times
6 were obtained from a T₂* map generated with a multi-gradient echo sequence by drawing
7 ROIs around the cortex of the kidney (an example is shown in Additional File 5) or a region of
8 the liver. At least one animal was culled at each time point for histological analyses, and
9 brains and kidneys were fixed with 4% formaldehyde and imaged at a higher resolution *post*
10 *mortem* (all MRI acquisition parameters are described in the Additional File 6). Tumours
11 were imaged with a T₂ weighted fast spin echo sequence.

12 Histopathological analysis

13 Perfusion fixed frozen brain and kidney sections were stained for the endothelial cell marker
14 isolectin B4 (IB4, L2140, Sigma Aldrich, UK) as described previously[48]. The presence of
15 ZsGreen⁺ mMSCs within brain and glomerular capillaries was imaged by confocal microscopy
16 (LSM 800 Airyscan, Zeiss). Frozen kidney sections (7µm) were stained for the presence of
17 iron (Iron Stain Kit, Sigma, UK) according to manufacturer's instructions to detect SPIONs,
18 and consecutive sections were counterstained with DAPI. Prussian blue stained cells and
19 ZsGreen-positive mMSCs were imaged by bright field and epifluorescence microscopy.
20 Tumours were fixed in 4% paraformaldehyde at 4°C for 24h, washed in PBS and processed
21 through an ethanol and xylene series before embedding in paraffin. Five µm tissue sections
22 were stained for haematoxylin and eosin (H&E) by standard methods and morphologically
23 assessed.

1

2 Fluorescence activated cell sorting (FACS)

3 Bone marrow was extracted as previously described[49]. In short, femurs and tibias were
4 collected in PBS containing penicillin/streptomycin, the bone marrow was flushed out with
5 PBS, centrifuged (400 g, 5 mins) and then resuspended in fresh PBS before analysis by flow
6 cytometry for ZsGreen expression.

7
8 Statistical Analyses

9 Statistical analyses were performed using Minitab 17 statistical software. A one-way analysis
10 of variance (ANOVA) was used to compare multiple groups. When an ANOVA resulted in a
11 statistically significant result ($p < 0.05$), a Tukey pairwise comparison was performed in order
12 to determine which groups were significantly different. The Tukey pairwise comparison
13 assigned each group at least one letter, and groups that did not share a letter were
14 significantly different from one another.

15

16

1 Results

2 Whole body biodistribution of different cell types following intravenous (IV) and intracardiac 3 (IC) administration

4 Bioluminescence imaging showed that IV delivery of ZsGreen⁺/Luc⁺ mouse MSCs (mMSCs),
5 mouse kidney-derived stem cells (mKSCs) and human kidney cells (hKCs) resulted in signals
6 exclusively in the lungs, while signals from IV-administered macrophages were also located
7 more posteriorly (Fig. 1a). This was expected because macrophages are known to traverse
8 the lungs and populate other organs, such as the liver and spleen. In contrast, intra-arterial
9 delivery via the left heart ventricle (from now on referred to as intra-cardiac (IC)) resulted in
10 a whole-body distribution of all cell types (Fig. 1a).

11 Organ-specific *ex vivo* imaging within 1h of IV administration of mKSCs confirmed that the
12 signal was limited to the lungs (Fig. 1b, d). In contrast, after IC administration,
13 bioluminescent signals were detected in the brain, heart, lungs, kidney, spleen, and liver (Fig.
14 1b, d). IV-administered macrophages were found predominantly within the lungs by *ex vivo*
15 imaging (Fig. 1c), but weaker signals were also detected in the spleen and liver, kidneys and
16 brain, confirming the *in vivo* signal distribution. *Ex vivo* analysis of macrophages after IC
17 injection showed signals in most organs that were imaged (Fig. 1c, e).

18 To monitor the temporal dynamics of macrophage migration, cells were labelled with GNRs,
19 injected IV, and monitored continuously for 4.5h using MSOT. Signal intensity began to
20 increase immediately in both the liver and spleen until around 90 min when it started to
21 plateau (Fig. 1f), but remained close to basal levels in the kidney, consistent with BLI *ex vivo*
22 analysis (Fig. 1e, f). However, when GNR-labelled macrophages were administered IC,
23 increases in signal intensity in the kidney were comparable to those in the liver and spleen
24 4h post-administration (quantification is shown in Additional File 4c).

1

2 Cell distribution within organs using high-resolution magnetic resonance imaging

3 Since the spatial resolution of BLI is poor, we used MRI to evaluate the intra-organ
4 biodistribution of ZsGreen⁺/Luc⁺/SPION⁺ mMSCs after IV or IC administration, focussing
5 particularly on the brain and kidneys. Following IC injection, T₂^{*} weighted imaging revealed
6 hypointense areas distributed homogenously throughout the brain (Fig. 2a), and localised in
7 the cortex of the kidneys (Fig. 2b). However, hypointense contrast was not detected in the
8 brain or kidneys of IV-injected mice, confirming that IV administration does not deliver
9 mMSCs to either of these organs (Fig. 2a, b). Post mortem MR imaging of extracted organs
10 performed at higher resolution confirmed the hypointense contrast throughout the brain
11 and in the renal cortex of IC-injected mice (Fig. 2a, b).

12 Histological analysis of ZsGreen expression by fluorescence microscopy in combination with
13 Prussian Blue staining of SPIONs showed that labelled cells were located in the renal
14 glomeruli (Fig. 2c). ZsGreen and Prussian Blue signals corresponded to the same spatial
15 location, indicating that hypointense contrast *in vivo* was unlikely to result from false-
16 positive detection of SPIONs (e.g. released from dead cells). To determine whether IC-
17 administered cells had undergone extravasation, we performed confocal imaging of IB4-
18 stained blood vessels **in organs within 5 hours after cell administration**. This demonstrated
19 that ZsGreen⁺ mMSCs were physically trapped in the lumen of microcapillaries (Fig. 2d),
20 suggesting that the cells did not cross the blood brain barrier or the glomerular filtration
21 barrier.

22

23 Short-term fate of IC-injected cells

1 To determine how long the cells persisted in major organs we injected 10^6
2 ZsGreen⁺/Luc⁺/SPION⁺ mMSCs into the left cardiac ventricle of BALB/c mice and tracked their
3 fate *in vivo* by MRI and BLI, and post mortem by MRI and fluorescence microscopy (Fig. 3a).
4 On the day of injection (**day 0**), whole-body distribution of IC-administered mMSCs by
5 bioluminescence signals was observed, while in the kidneys, MRI revealed hypointense
6 contrast specifically in the cortex. By **day 1**, the bioluminescence signal intensity decreased,
7 suggesting cell death. Correspondingly, fewer hypointense areas were observed in the renal
8 cortex by MRI, supporting the disappearance of SPION-labelled cells. By **day 2**,
9 bioluminescence was no longer detectable in the abdominal region, nor was any significant
10 hypointense SPION contrast observed in the kidneys with MRI. This was confirmed by high-
11 resolution MRI of organs *ex vivo*, showing a decrease in contrast in the renal cortex over
12 time, and a decrease in the frequency of ZsGreen⁺ mMSCs in kidney glomeruli by
13 fluorescence microscopy (Fig. 3a). Changes in the T_2^* relaxation time in the renal cortex
14 indicated the relative number of SPION-labelled cells present at each time point. T_2^* was
15 significantly lower on the day of cell administration (Fig. 3b) than at baseline but then
16 increased towards baseline levels at **day 1** and **day 2**. Because the liver is the major organ for
17 clearance of blood-transported particulates, we quantified the hepatic T_2^* relaxation time,
18 which revealed a subtle but significant decrease from baseline through to **day 2** (Fig. 3c).
19 These results suggest that following cell death, SPIONs accumulate predominantly in the
20 liver and are not retained by the kidneys.

21

22 Effect of administration route on the long-term biodistribution and fate of mMSCs

23 To assess the effect of administration route on the long-term fate of cells, ZsGreen⁺/Luc⁺
24 mMSCs were administered to BALB/c SCID mice by IC or IV routes, and biodistribution

1 monitored by BLI at multiple time points over 28 days. While both IC and IV injection
2 resulted in the typical immediate biodistribution patterns (Fig. 1a), by day 4 following IV and
3 IC administration, the bioluminescence signal was undetectable, indicating loss of cells via
4 cell death (Fig. 4a). Continued imaging over time showed that bioluminescence signals began
5 to increase again in animals after IC injection from around day 14, but not in animals after IV
6 injection. The increase in signal was particularly prominent in the hindquarters of all five IC-
7 injected mice at day 14, and increased further until day 30 (Fig. 4a, Additional File 7a).
8 Detailed analysis of animals after IV administration of mMSCs revealed that bioluminescence
9 signals in the lungs of one mouse increased over time (Additional File 7b). Overall, whole-
10 body bioluminescence intensity initially decreased following both IC and IV administration,
11 and subsequently increased rapidly in the IC-injected mice (Fig. 4b-d).

12 Osteosarcoma formation after IC administration of mMSCs

13 Multiple abnormal growths were present in IC-injected BALB/c SCID mice, predominantly in
14 skeletal muscle surrounding the femurs, but also in muscle near the hips, ribs, and spine (Fig.
15 5a, f), suggesting tumours had formed. Tumour sites corresponded to foci of intense BLI
16 signals which could also be identified using T₂ weighted MR imaging (Fig. 4e). Furthermore,
17 T₂ weighted MR imaging allowed us to detect an abnormal mass in the lungs of one (out of
18 three) IV-injected mouse that displayed an intense bioluminescence signal (Fig. 4e,
19 Additional File 7b). Although cells of the mMSC line have been suggested to home to the
20 bone marrow[50], flow cytometry analysis showed the bone marrow was negative for
21 ZsGreen⁺ cells (Additional File 8). Histologically, tumours were characterised by atypical solid
22 proliferation of spindle cells associated with multifocal formation of pale amorphous
23 eosinophilic material (osteoid). The tumours were therefore classified as osteosarcomas (Fig.

1 5h, j, k). Frozen sections of the tumour tissue exhibited specific ZsGreen fluorescence (Fig.
2 5i), further confirming the neoplasms originated from mMSCs.

3 Chromosomal analysis of the mMSCs revealed a grossly abnormal karyotype of between 65
4 and 67 chromosomes, with multiplications and unidentified chromosomes (shown in
5 Additional File 9a).

6 Formation of mMSC-derived tumours in different mouse strains

7 To determine whether tumours developed because the BALB/c SCID mice were
8 immunocompromised, we investigated the long-term fate of the mMSCs following IC
9 administration in three different immunocompetent mouse strains: BALB/c (same genetic
10 background as mMSCs), FVB (unrelated inbred strain), and MF1 (unrelated outbred strain).
11 The biodistribution immediately after injection was similar between the strains, but at day
12 28, only the BALB/c mice displayed bioluminescence signals as high as those in the BALB/c
13 SCID mice (Fig. 5a-d). Moreover, the timing and location of tumour formation was consistent
14 in all immunocompetent and immunocompromised BALB/c mice. In the FVB and MF1
15 strains, mMSC foci tended to form in similar locations as with the BALB/c mice, but
16 bioluminescence signals were weaker. Although signal intensity gradually increased in FVB
17 mice from d7 to d28, in MF1 outbred mice, signals increased initially up to d21, but then
18 started to decrease as the mMSC foci began to regress (Fig. 5e).

19 Long-term biodistribution of hUC-MSCs in BALB/c SCID mice

20 Since mMSCs gave rise to tumours in immuno-compromised and –competent mice,
21 predominantly after systemic arterial injection, we aimed to determine whether clinically
22 relevant MSCs could carry a similar health risk. We focussed on well-studied hBM-MSCs as

1 well as hUC-MSCs, as the latter are currently being used in an increasing number of clinical
2 trials (Additional File 1). The chromosomal analysis for both hBM-MSCs and hUC-MSCs
3 revealed a normal karyotype (Additional File 9b,c). We analysed the long-term fate of hUC-
4 MSCs via the IC and IV route at two different cell doses, 1×10^6 and 5×10^5 , showing
5 consistent results (Table 1).

6 When following the fate of both of these cell types after IV or IC administration in BALB/c
7 SCID mice, we found that in most cases, BLI signals became weaker within a few days of
8 administration, and remained undetectable for the duration of the study (hBM-MSCs: 4
9 weeks; hUC-MSCs: 8 weeks) (Fig. 6a). Ex vivo analysis of the organs on the day of injection
10 suggested that similar to the other cell types, a whole-body distribution is obtained when
11 cells are injected into the arterial system, and cells are mostly trapped in the lungs when the
12 venous route is used. However, in the case of hUC-MSCs, BLI signal was sometimes observed
13 in the heart (Figure 6b). When imaging the same organs without the lungs, and with an
14 increased detection sensitivity, the signal in the heart became more obvious, while very
15 weak signals could also be observed in other organs (Additional File 10). Interestingly, long-
16 term imaging of mice that had received hUC-MSCs via the IV route revealed that in a small
17 number of animals (~25%) foci had developed in locations beyond the lungs (Fig. 6c, red
18 arrows), although in all cases these regressed within the time course of the experiment.

1 **Discussion**

2
3
4
5 3 Here, we have employed a novel platform approach of non-invasive preclinical imaging
6
7 4 encompassing BLI, MRI and MSOT to assess the biodistribution and persistence of a range of
8
9
10 5 mouse and human cell types following IV and IC administration in healthy mice. These cells
11
12 6 included mouse MSCs, kidney stem cells and macrophages, as well as human kidney-derived
13
14
15 7 cells and two types of human MSCs, which are already being tested as cell therapies in
16
17
18 8 clinical trials.

19
20 9 As expected, immediate analysis after IV administration revealed that apart from
21
22
23 10 macrophages, all other cell types were mostly sequestered in the lungs, although small
24
25
26 11 numbers of hUC-MSCs could be detected in other organs following *ex vivo* analysis. After IC
27
28 12 administration, all cell types showed a widespread distribution. However, irrespective of the
29
30
31 13 administration route, analysis using **BLI and MRI** determined that cells disappeared from
32
33
34 14 major organs within 24-48 hours, which based on the loss of BLI signals, was likely due to cell
35
36 15 death.

37
38 16 **A number of preclinical cell therapy studies have reported that IV administered cells reached**
39
40
41 17 **the relevant injured organs, where they incorporated and contributed to the regeneration of**
42
43
44 18 **healthy and functional tissue [7, 9, 10, 51, 52]. It had been postulated that the mechanisms**
45
46 19 **by which the cells, especially MSCs, reached the injured organs was based on the release of**
47
48
49 20 **trophic factors which attracted the cells to the relevant injury site [33, 53]. An important**
50
51
52 21 **problem with these studies was that cells had mostly been labelled with membrane dyes (DiI**
53
54 22 **or PKH26) which were detected in the injured organ; however, as we have recently**
55
56
57 23 **demonstrated, membrane dyes easily dissociate from the cells, leading to misinterpretation**
58
59 24 **of the presence of administered cells [32]. Therefore, more sophisticated approaches to cell**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 labelling and tracking have been established, including bioluminescence imaging of
2 luciferase-transduced cells [17, 54]. This method is specific to living cells because the signal is
3 dependent on production of the enzyme firefly luciferase. Here, we have demonstrated, as
4 others before [32, 34, 55, 56], that IV administered cells are generally sequestered in the
5 first vascular bed they encounter, which is the lung microvasculature, where they die and
6 then disappear within 2 days.

7 Since a number of preclinical studies have shown that administered cells fail to incorporate
8 and directly contribute to the regeneration of the damaged tissue in injured organs despite
9 leading to beneficial effects in organ function and histology, it is highly relevant to
10 understand the mechanisms by which efficacy is provided. Increasing evidence points
11 towards paracrine factors that are released by the dying cells, with beneficial effects on
12 organ function. This probably occurs through activation of immunomodulatory pathways
13 that initiate regeneration or, possibly, also via other protective functions [31, 32, 56]. It is
14 currently not understood whether these effects are based on direct and short-term
15 interactions between cytokines and immune cells, stimulating an anti-inflammatory switch,
16 or if epigenetic changes are involved, which could lead to long-term effects.

17 We explored an alternative systemic administration route by injecting cells directly into the
18 left ventricle, and demonstrated that this route delivered the cells directly to organs, instead
19 of sequestration in the lungs. Our observation that cells are cleared very quickly from the
20 major organs following IC administration indicates that the arterial route poses no significant
21 advantage for cell therapy administration. However, it is possible that small numbers of cells
22 reaching the organs after IC administration may still be able to locally exert beneficial roles
23 through paracrine effects before they are cleared. Therefore, further research is required to
24 explore the local role of IC delivered cells.

1 Using our platform of imaging techniques, we were able to provide some mechanistic insight
2 into the fate of macrophages after administration, which have been demonstrated to confer
3 beneficial effects in organ injury models [57, 58]. Macrophages have been previously shown
4 to home to the liver and spleen after passage through the lungs [59]. However, the dynamics
5 of this homing process had not been described. Using multi-modal BLI and MSOT [24], we
6 could monitor macrophage accumulation in the liver and spleen for 4.5h continuously at
7 high temporal resolution. We found that labelled macrophages immediately started to
8 accumulate in liver and spleen, particularly in the first ~90 min, which indicated that some of
9 the macrophages instantly passed through the pulmonary circulation.

10 While BLI has the advantage of highly sensitive body-wide detection of luciferase-expressing
11 cells, its spatial resolution is poor, which prevents organ-focussed imaging. To visualise cells
12 within major organs such as kidney and brain, and monitor their fate over time, we
13 implemented a bimodal approach comprising BLI and MRI, taking advantage of the high
14 spatial resolution of MRI in addition to the high sensitivity of BLI and the fact that luciferase
15 activity is dependent on cell viability[15-18].

16 It should be noted that labelling of cells for preclinical imaging approaches raises a number
17 of questions regarding the interpretation of the findings. While lentiviral labelling is typically
18 a process that results in stable expression of the reporter protein of interest, and as in our
19 case of luciferase, with high sensitivity, exposure to lentiviral particles and the resulting
20 expression of exogenous proteins could possibly affect the immunogenicity of the cells [60],
21 which may have downstream effects on recognition by the endogenous immune system.
22 Because we have used SCID mice for most of our studies, especially those with human MSCs,
23 possible immunogenicity will unlikely have affected the results. In addition, luciferase signal
24 will disappear when cells are phagocytosed, but may remain if cells undergo cell fusion.

1 Therefore, loss of BLI signal is a clear sign of loss of cells through cell death, while continued
2 presence of signal could also indicate a change in cell phenotype by cell fusion. By contrast,
3 SPION or GNR labels may still be detectable after cells have been phagocytosed or fused,
4 potentially leading to misinterpretation. To our knowledge, SPIONs and GNRs have not
5 shown to modify the immunogenicity of labelled cells. To avoid false signals, dual or triple
6 labelling of cells using a combination of genetic direct reporters and nanoparticles could
7 address this problem. We have recently shown that a combination of labels can indeed
8 provide detailed information on the dynamics of cell fate, as GNR-labelled mouse MSCs
9 which also expressed a near infrared reporter protein, disappeared within 2 days after IC
10 injection from the various organs in which they could be detected initially, and instead GNRs
11 accumulated in the liver. By contrast, the reporter protein visualised the increase in cells in
12 tumours forming in sites similar to the ones reported here [24]. A genetic reporter is highly
13 suitable for the detection of multiplying cells, for example in tumours, where the GNRs or
14 other nanoparticles would get diluted out with increasing numbers of cell divisions.

15 Our detailed analysis of the biodistribution of mMSCs after IC injection using *in vivo*, and
16 subsequently *ex vivo* MR imaging techniques revealed that SPION-labelled cells were
17 scattered throughout the brain, while in the kidneys, they were restricted to the cortical
18 regions. *Ex vivo* histological staining and fluorescence microscopy demonstrated that cells in
19 the kidneys were found only within the glomeruli, bounded by endothelial cells within the
20 microvasculature, where they appeared to be trapped. Similarly, cells in the brain were only
21 localised within the microvasculature, indicating that they lack the capacity to pass through
22 the blood brain barrier. These results demonstrate that the mMSCs cannot extravasate into
23 the brain and kidneys.

1 During long-term cell tracking of the BALB/c-derived mMSCs, we observed tumour formation
2 in skeletal muscle following IC administration to a similar degree in immune-competent
3 BALB/c mice as in BALB/c SCIDs. mMSCs also gave rise to tumours in an unrelated inbred
4 strain, albeit at a slower rate, while in an unrelated outbred strain, small foci of mMSCs
5 expanded at early time points and later regressed. Taken together, these data suggest that
6 the adaptive immune system might not be able to recognise tumours derived from
7 syngeneic MSCs, and that the genetic background of the host appears to have an effect on
8 the propensity of MSCs to form tumours. This could be a concern for human trials using
9 autologous MSCs where the ability of the cells to form tumours may not be detected by the
10 recipient's immune system. Furthermore, the results suggest that the risk of tumour
11 formation might depend on undefined genetic factors that would vary from patient to
12 patient. However, it is important to note that karyotype testing of the mMSC line used here
13 revealed a range of chromosomal abnormalities, which could contribute to their propensity
14 to form tumours. In a recent study, a clonal mouse MSC line derived from the
15 immortomouse was found to persist for up to 33 weeks after intra-arterial injection, in the
16 distal femur of SCID mice in which the respective leg had been injured by irradiation [55].
17 However, while the BLI signal of firefly luciferase expressed by the mMSCs increased over
18 time, tumours were not reported.

19 Our observation that mMSCs distributed to most organs following IC injection, but tumours
20 were predominantly localised in the skeletal muscles and not within the organs they
21 originally appeared in, raises the question of how tumour formation is regulated in different
22 organs and tissues. Our data indicate that the cells had a 'survival advantage' in muscular
23 tissue, but not in the brain and the kidneys, from which they failed to extravasate. We
24 hypothesise that following IC administration, a small number of MSCs were able to

1 extravasate from the capillaries in the skeletal muscle where they started to proliferate. The
2 mechanisms that regulate the ability of the mMSCs to extravasate and form tumours in the
3 skeletal muscle but not in other organs are not known, and further analysis is required to
4 determine the molecular and cellular factors controlling this process.
5 Our results also show that the cells failed to home to and populate the bone marrow, which
6 is surprising given the cells had been originally isolated from the bone marrow[61]. The D1
7 mMSC line used here has not previously been reported to generate invasive tumours, since
8 subcutaneously injected cells provided no evidence of metastasizing, even if they
9 proliferated at the injection site[23, 62]. Our observation that the mMSCs did not form
10 tumours outside the lung following IV administration is therefore consistent with this
11 finding. However, the formation of osteosarcomas in the skeletal muscle after IC
12 administration of mMSCs in this study is in line with the previously described formation of
13 osteosarcomas after adoptive transfer of primary MSCs, particularly for cells expanded *in*
14 *vitro*, and is a major safety concern in therapies using MSCs[63, 64].
15 Since these observations suggested that arterial administration of MSC-based cell therapies
16 could have important safety implications, we followed the fate of MSC derived from the
17 bone marrow or the umbilical cord of healthy human donors. We confirmed that neither of
18 these cells presented any major chromosomal aberrations, even after transduction with the
19 luciferase reporter. While in most animals the cells became undetectable within a few days
20 after IV administration, in a few mice the hUC-MSCs persisted longer, albeit transiently, in
21 other body regions where their presence was not expected. Of note, a transient persistence
22 of hUC-MSCs was not observed after IC administration, nor for hBM-MSCs using IV or IC
23 administration routes. We suggest that this unusual behaviour is not linked to cell size,
24 because the hUC-MSCs are not smaller than mKSCs or mMSCs, but could possibly be due to

1 their surface proteins, allowing some of the cells to escape the lungs[33, 65]. The
2 observation that hUC-MSC foci appeared in a small number of mice, grew in size, but later
3 disappeared, was difficult to explain, especially given that the mice were SCIDs and thus
4 lacked an adaptive immune system. It is possible that the cells eventually elicited a
5 xenogeneic response involving macrophages and natural killer cells[66], after initially
6 suppressing the native immune system, which is one of their central properties[67, 68].
7 Alternatively, the hUC-MSCs may have expanded in the animal but then become senescent
8 and died, irrespective of the host's ability to mount an immune response. Thus, after an 8-
9 week period of cell tracking, we could not observe any tumour growth by *in vivo* or *ex vivo*
10 BLI in all SCID mice to which hUC-MSCs had been administered by either IV or IC injection.
11 However, the observation that the IV-injected hUC-MSCs persisted for a time period in 25%
12 of the animals indicates that these cells carry greater safety risks and suggests that clinical
13 therapies with these cells should proceed with caution with an appropriate risk management
14 plan. Further preclinical studies are needed to determine the mechanisms by which hUC-
15 MSCs were able to persist as well as eventually disappear in order to better define the
16 potential for tumourigenicity. The imaging platform presented here provides the necessary
17 biotechnology for preclinical evaluation of the potential tumourigenicity of cell products
18 used for cell transplantation, for which there is presently no internationally recognised
19 guideline.

21 **Conclusions**

22 Cell-based therapies are currently being considered for a range of diseases, some of which
23 are already undergoing clinical trials. A robust biodistribution and safety assessment is
24 essential for understanding cell fate and ensuring patient welfare. Here, we demonstrate a

1 safety assessment platform that can expose not only the general organ distribution of
2 potential cell therapies, but also a detailed view of their presence within different organs.
3 Importantly, by using this imaging platform, we show that the route of administration affects
4 the range of organs that the cells can reach, and, particularly, their propensity to form
5 tumours. Our assessment suggests that cells are short-lived irrespective of whether they are
6 administered via the venous or arterial circulation, and that the risk of cell persistence or
7 tumour formation is dependent on the cell type, route of administration and immune status
8 of the host. Crucially, we show that clinically used, human umbilical cord-derived
9 mesenchymal stem/stromal cells form transient unexpected self-limited proliferations in
10 various anatomical regions when administrated intravenously. The implications of this
11 observation require further investigations and should be taken into account when clinical
12 trials are considered.

14 **List of Abbreviations:**

15 ANOVA: analysis of variance

16 BLI: bioluminescence imaging

17 FACS: fluorescence activated cell sorting

18 GNRs: gold nanorods

19 hBM-MSCs: human bone marrow-derived mesenchymal stem/stromal cells

20 hKCs: human kidney cells

21 hUC-MSCs: human umbilical cord-derived mesenchymal stem/stromal cells

22 H&E: haematoxylin and eosin

23 IC: intracardiac

24 IV: intravenous

- 1 luc: luciferase (from firefly)
- 2 MRI: magnetic resonance imaging
- 3 MSCs: mesenchymal stem/stromal cells
- 4 mKSCs: mouse kidney-derived stem cells
- 5 mMSCs: mouse mesenchymal stem/stromal cells (D1 line)
- 6 MOI: multiplicity of infection
- 7 MSOT: multispectral optoacoustic tomography
- 8 PBS: phosphate buffered saline
- 9 PCV: packed cell volume
- 10 RMTs: regenerative medicine therapies
- 11 ROI: region of interest
- 12 SCID: severe combined immunodeficient
- 13 SPIONs: superparamagnetic iron oxide nanoparticles

14

15 **Declarations:**

16 **Ethics approval and consent to participate**

17 All animal experiments were performed under a licence granted under the revised UK
18 Animals (Scientific Procedures) Act 1986 and were approved by the University of Liverpool
19 ethics committee.

20 **Consent for publication:**

21 Not applicable

22 **Availability of data and materials:**

23 The datasets supporting the conclusions of this article are included within the article and its
24 additional files.

1 **Competing interests:**

2 The authors declare that they have no competing interests.

3 **Funding:**

4 We gratefully acknowledge support by the MRC, EPSRC and BBSRC-funded UK Regenerative
5 Medicine Platform “Safety and Efficacy, focussing on Imaging Technologies Hub”
6 (MR/K026739/1), by a Marie Curie Fellowship to Joan Comenge (NANOSTEMCELLTRACKING),
7 and by the FP7 Marie Curie Initial Training Network ‘NephroTools’ and Alder Hey Children’s
8 Kidney Fund. The funding bodies had no role in the design of the study and collection,
9 analysis, and interpretation of data, nor in the writing of the manuscript. Cai Astley and Lydia
10 Beeken were self-funded in this project.

11 **Author Contributions:**

12 L.S., A.T., J.Sh., R.H., L.B., C.A.: conception and design, acquisition and/or assembly of data,
13 data analysis and interpretation, manuscript writing, final approval of manuscript
14 M.B., J.C., I.S., L.R.: acquisition and/or assembly of data, final approval of manuscript
15 J.Sm., E.A.: provision of study material, final approval of manuscript
16 C.H., R.L., M.J.R., D.J.A., H.P., B.K.P.: conception and design, data analysis and interpretation,
17 final approval of manuscript
18 P.M., B.W.: conception and design, data analysis and interpretation, manuscript writing, final
19 approval of manuscript

20 **Acknowledgements:**

21 The authors would like to thank Carmel Moran and Adrian Thomson, University of
22 Edinburgh, Tammy Kalber and Daniel Stuckey University College London, and Aleksandra
23 Rak-Raszewska, for providing help and technical guidance in optimising the US-IC injection

1 method, and Thomas Wilm, University of Liverpool, for help with the confocal imaging. All *in*
2 *vivo* imaging was carried out in the Centre for Preclinical Imaging, University of Liverpool.

11 **References:**

- 12 1. Buzhor E, Leshansky L, Blumenthal J, Barash H, Warshawsky D, Mazor Y, Shtrichman
13 R: **Cell-based therapy approaches: The hope for incurable diseases.** *Regenerative*
14 *Medicine* 2014, **9**:649-672.
- 15 2. Heslop JA, Hammond TG, Santeramo I, Tort Piella A, Hopp I, Zhou J, Baty R, Graziano
16 El, Proto Marco B, Caron A, et al: **Concise review: workshop review: understanding**
17 **and assessing the risks of stem cell-based therapies.** *Stem Cells Transl Med* 2015,
18 **4**:389-400.
- 19 3. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J,
20 Stewart DJ: **Safety of cell therapy with mesenchymal stromal cells (SafeCell): a**
21 **systematic review and meta-analysis of clinical trials.** *PLoS One* 2012, **7**:e47559.
- 22 4. Toyserkani N, Gustaf Jørgensen M, Tabatabaeifar S, Jensen C, Sheikh S, Sørensen J:
23 **Concise Review: A Safety Assessment of Adipose-Derived Cell Therapy in Clinical**
24 **Trials: A Systematic Review of Reported Adverse Events: Safety of Adipose-Derived**
25 **Cell Therapy.** *Stem Cells Transl Med* 2017, **6**:1786–1794.
- 26 5. Li X, Bai J, Ji X, Li R, Xuan Y, Wang Y: **Comprehensive characterization of four**
27 **different populations of human mesenchymal stem cells as regards their immune**
28 **properties, proliferation and differentiation.** *Int J Mol Med* 2014, **34**:695-704.

- 1 6. Berkowitz AL, Miller MB, Mir SA, Cagney D, Chavakula V, Guleria I, Aizer A, Ligon KL,
2 Chi JH: **Glioproliferative Lesion of the Spinal Cord as a Complication of “Stem-Cell
3 Tourism”**. *New England Journal of Medicine* 2016, **375**:196-198.
- 4 7. Jang HR, Park JH, Kwon GY, Lee JE, Huh W, Jin HJ, Choi SJ, Oh W, Oh HY, Kim YG:
5 **Effect of preemptive treatment with human umbilical cord blood-derived
6 mesenchymal stem cells on the development of renal ischemia-reperfusion injury
7 in mice**. *Am J Physiol Renal Physiol* 2014, **307**:F1149-1161.
- 8 8. Chen YT, Sun CK, Lin YC, Chang LT, Chen YL, Tsai TH, Chung SY, Chua S, Kao YH, Yen
9 CH, et al: **Adipose-derived mesenchymal stem cell protects kidneys against
10 ischemia-reperfusion injury through suppressing oxidative stress and inflammatory
11 reaction**. *J Transl Med* 2011, **9**:51.
- 12 9. Ronconi E, Sagrinati C, Angelotti ML, Lazzeri E, Mazzinghi B, Ballerini L, Parente E,
13 Becherucci F, Gacci M, Carini M, et al: **Regeneration of glomerular podocytes by
14 human renal progenitors**. *J Am Soc Nephrol* 2009, **20**:322-332.
- 15 10. Angelotti ML, Ronconi E, Ballerini L, Peired A, Mazzinghi B, Sagrinati C, Parente E,
16 Gacci M, Carini M, Rotondi M, et al: **Characterization of renal progenitors
17 committed toward tubular lineage and their regenerative potential in renal tubular
18 injury**. *Stem Cells* 2012, **30**:1714-1725.
- 19 11. Morigi M, Introna M, Imberti B, Corna D, Abbate M, Rota C, Rottoli D, Benigni A,
20 Perico N, Zoja C, et al: **Human bone marrow mesenchymal stem cells accelerate
21 recovery of acute renal injury and prolong survival in mice**. *Stem Cells* 2008,
22 **26**:2075-2082.
- 23 12. Li P, Zhang R, Sun H, Chen L, Liu F, Yao C, Du M, Jiang X: **PKH26 can transfer to host
24 cells in vitro and vivo**. *Stem Cells Dev* 2013, **22**:340-344.
- 25 13. Taylor A, Wilson KM, Murray P, Fernig DG, Levy R: **Long-term tracking of cells using
26 inorganic nanoparticles as contrast agents: are we there yet?** *Chem Soc Rev* 2012,
27 **41**:2707-2717.
- 28 14. Kircher MF, Gambhir SS, Grimm J: **Noninvasive cell-tracking methods**. *Nat Rev Clin
29 Oncol* 2011, **8**:677-688.
- 30 15. Paley MA, Prescher JA: **Bioluminescence: a versatile technique for imaging cellular
31 and molecular features**. *MedChemComm* 2014, **5**:255-267.

- 1 16. Lyons SK, Patrick PS, Brindle KM: **Imaging mouse cancer models in vivo using**
2 **reporter transgenes.** *Cold Spring Harb Protoc* 2013, **2013**:685-699.
- 3 17. Scarfe L, Brilliant N, Kumar JD, Ali N, Alrumayh A, Amali M, Barbellion S, Jones V,
4 Niemeijer M, Potdevin S, et al: **Preclinical imaging methods for assessing the safety**
5 **and efficacy of regenerative medicine therapies.** *npj Regenerative Medicine* 2017,
6 **2**:28.
- 7 18. Kim JE, Kalimuthu S, Ahn B-C: **In Vivo Cell Tracking with Bioluminescence Imaging.**
8 *Nuclear Medicine and Molecular Imaging* 2015, **49**:3-10.
- 9 19. Togel F, Yang Y, Zhang P, Hu Z, Westenfelder C: **Bioluminescence imaging to monitor**
10 **the in vivo distribution of administered mesenchymal stem cells in acute kidney**
11 **injury.** *Am J Physiol Renal Physiol* 2008, **295**:F315-321.
- 12 20. Wise AF, Williams TM, Kiewiet MB, Payne NL, Siatskas C, Samuel CS, Ricardo SD:
13 **Human mesenchymal stem cells alter macrophage phenotype and promote**
14 **regeneration via homing to the kidney following ischemia-reperfusion injury.** *Am J*
15 *Physiol Renal Physiol* 2014, **306**:F1222-1235.
- 16 21. Ricles LM, Nam SY, Trevino EA, Emelianov SY, Suggs LJ: **A Dual Gold Nanoparticle**
17 **System for Mesenchymal Stem Cell Tracking.** *J Mater Chem B Mater Biol Med* 2014,
18 **2**:8220-8230.
- 19 22. Jokerst JV, Thangaraj M, Kempen PJ, Sinclair R, Gambhir SS: **Photoacoustic Imaging**
20 **of Mesenchymal Stem Cells in Living Mice via Silica-Coated Gold Nanorods.** *ACS*
21 *nano* 2012, **6**:5920-5930.
- 22 23. Comenge J, Fragueiro O, Sharkey J, Taylor A, Held M, Burton NC, Park BK, Wilm B,
23 Murray P, Brust M, Levy R: **Preventing Plasmon Coupling between Gold Nanorods**
24 **Improves the Sensitivity of Photoacoustic Detection of Labeled Stem Cells in Vivo.**
25 *ACS Nano* 2016, **10**:7106-7116.
- 26 24. Comenge J, Sharkey J, Fragueiro O, Wilm B, Brust M, Murray P, Levy R, Plagge A:
27 **Multimodal cell tracking from systemic administration to tumour growth by**
28 **combining gold nanorods and reporter genes.** *eLife* 2018, **7**:e33140.
- 29 25. Barrow M, Taylor A, García Carrión J, Mandal P, Park BK, Poptani H, Murray P,
30 Rosseinsky MJ, Adams DJ: **Co-precipitation of DEAE-dextran coated SPIONs: how**
31 **synthesis conditions affect particle properties, stem cell labelling and MR contrast.**
32 *Contrast Media and Molecular Imaging* 2016, **11**:362-370.

1 26. Barrow M, Taylor A, Nieves DJ, Bogart LK, Mandal P, Collins CM, Moore LR, Chalmers
2 JJ, Lévy R, Williams SR, et al: **Tailoring the surface charge of dextran-based polymer**
3 **coated SPIONs for modulated stem cell uptake and MRI contrast.** *Biomaterials*
4 *Science* 2015, **3**:608-616.

5 27. Barrow M, Taylor A, Murray P, Rosseinsky MJ, Adams DJ: **Design considerations for**
6 **the synthesis of polymer coated iron oxide nanoparticles for stem cell labelling and**
7 **tracking using MRI.** *Chemical Society Reviews* 2015, **44**:6733-6748.

8 28. Ittrich H, Lange C, Tögel F, Zander AR, Dahnke H, Westenfelder C, Adam G, Nolte-
9 Ernsting C: **In vivo magnetic resonance imaging of iron oxide–labeled, arterially-**
10 **injected mesenchymal stem cells in kidneys of rats with acute ischemic kidney**
11 **injury: Detection and monitoring at 3T.** *Journal of Magnetic Resonance Imaging*
12 2007, **25**:1179-1191.

13 29. Papazova DA, Oosterhuis NR, Gremmels H, van Koppen A, Joles JA, Verhaar MC: **Cell-**
14 **based therapies for experimental chronic kidney disease: a systematic review and**
15 **meta-analysis.** *Dis Model Mech* 2015, **8**:281-293.

16 30. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP:
17 **Stem Cell Transplantation: The Lung Barrier.** *Transplantation Proceedings* 2007,
18 **39**:573-576.

19 31. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L,
20 Delafontaine P, Prockop DJ: **Intravenous hMSCs improve myocardial infarction in**
21 **mice because cells embolized in lung are activated to secrete the anti-inflammatory**
22 **protein TSG-6.** *Cell Stem Cell* 2009, **5**:54-63.

23 32. Santeramo I, Perez ZH, Illera A, Taylor A, Kenny S, Murray P, Wilm B, Gretz N: **Human**
24 **kidney-derived cells ameliorate acute kidney injury without engrafting into renal**
25 **tissue.** *Stem Cells Translational Medicine (In Press)* 2017.

26 33. Leibacher J, Henschler R: **Biodistribution, migration and homing of systemically**
27 **applied mesenchymal stem/stromal cells.** *Stem Cell Research & Therapy* 2016, **7**:7.

28 34. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, Baan CC,
29 Dahlke MH, Hoogduijn MJ: **Mesenchymal stem cells are short-lived and do not**
30 **migrate beyond the lungs after intravenous infusion.** *Frontiers in Immunology* 2012,
31 **3**:297.

- 1 35. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI:
2 **Pulmonary passage is a major obstacle for intravenous stem cell delivery: the**
3 **pulmonary first-pass effect.** *Stem Cells Dev* 2009, **18**:683-692.
- 4 36. Morigi M, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M, Rottoli D, Angioletti S,
5 Benigni A, Perico N, et al: **Mesenchymal stem cells are renotropic, helping to repair**
6 **the kidney and improve function in acute renal failure.** *J Am Soc Nephrol* 2004,
7 **15**:1794-1804.
- 8 37. Zhuo W, Liao L, Fu Y, Xu T, Wu W, Yang S, Tan J: **Efficiency of endovenous versus**
9 **arterial administration of mesenchymal stem cells for ischemia-reperfusion-**
10 **induced renal dysfunction in rats.** *Transplant Proc* 2013, **45**:503-510.
- 11 38. **Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted**
12 **Myocardium.** 2011:<https://clinicaltrials.gov> Identifier No NCT00548613.
- 13 39. Walter DH, Krankenberg H, Balzer JO, Kalka C, Baumgartner I, Schluter M, Tonn T,
14 Seeger F, Dimmeler S, Lindhoff-Last E, et al: **Intraarterial administration of bone**
15 **marrow mononuclear cells in patients with critical limb ischemia: a randomized-**
16 **start, placebo-controlled pilot trial (PROVASA).** *Circ Cardiovasc Interv* 2011, **4**:26-37.
- 17 40. Squillaro T, Peluso G, Galderisi U: **Clinical Trials with Mesenchymal Stem Cells: An**
18 **Update.** *Cell Transplantation* 2016, **25**:829-848.
- 19 41. **Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and**
20 **Chronic Kidney Disease (CKD).** 2017:<https://clinicaltrials.gov> Identifier No
21 NCT02525263.
- 22 42. **Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients.**
23 2016:<https://clinicaltrials.gov> Identifier No NCT01845350.
- 24 43. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA,
25 Everitt J, Farningham DAH, Glennie MJ, et al: **Guidelines for the welfare and use of**
26 **animals in cancer research.** *Br J Cancer* 2010, **102**:1555-1577.
- 27 44. Fuente Mora C, Ranghini E, Bruno S, Bussolati B, Camussi G, Wilm B, Edgar D, Kenny
28 SE, Murray P: **Differentiation of podocyte and proximal tubule-like cells from a**
29 **mouse kidney-derived stem cell line.** *Stem Cells Dev* 2012, **21**:296-307.
- 30 45. Taylor A, Herrmann A, Moss D, See V, Davies K, Williams SR, Murray P: **Assessing the**
31 **efficacy of nano- and micro-sized magnetic particles as contrast agents for MRI cell**
32 **tracking.** *PLoS One* 2014, **9**:e100259.

- 1 46. Kutner RH, Zhang XY, Reiser J: **Production, concentration and titration of**
2 **pseudotyped HIV-1-based lentiviral vectors.** *Nat Protoc* 2009, **4**:495-505.
- 3 47. Nikoobakht B, El-Sayed MA: **Preparation and growth mechanism of gold nanorods**
4 **(NRs) using seed-mediated growth method.** *Chemistry of Materials* 2003, **15**:1957-
5 1962.
- 6 48. Wälchli T, Mateos JM, Weinman O, Babic D, Regli L, Hoerstrup SP, Gerhardt H,
7 Schwab ME, Vogel J: **Quantitative assessment of angiogenesis, perfused blood**
8 **vessels and endothelial tip cells in the postnatal mouse brain.** *Nat Protocols* 2015,
9 **10**:53-74.
- 10 49. Sharkey J, Starkey Lewis PJ, Barrow M, Alwahsh SM, Noble J, Livingstone E, Lennen
11 RJ, Jansen MA, Carrion JG, Liptrott N, et al: **Functionalized superparamagnetic iron**
12 **oxide nanoparticles provide highly efficient iron-labeling in macrophages for**
13 **magnetic resonance-based detection in vivo.** *Cytotherapy* 2017, **19**:555-569.
- 14 50. Balian G, Wang GJ, Diduch D, Hahn C: **Pluripotential bone marrow cell line and**
15 **methods of using the same.** Google Patents; 2000.
- 16 51. Xing L, Cui R, Peng L, Ma J, Chen X, Xie RJ, Li B: **Mesenchymal stem cells, not**
17 **conditioned medium, contribute to kidney repair after ischemia-reperfusion injury.**
18 *Stem Cell Res Ther* 2014, **5**:101.
- 19 52. Sagrinati C, Netti GS, Mazzinghi B, Lazzeri E, Liotta F, Frosali F, Ronconi E, Meini C,
20 Gacci M, Squecco R, et al: **Isolation and characterization of multipotent progenitor**
21 **cells from the Bowman's capsule of adult human kidneys.** *J Am Soc Nephrol* 2006,
22 **17**:2443-2456.
- 23 53. Schenk S, Mal N, Finan A, Zhang M, Kiedrowski M, Popovic Z: **Monocyte chemotactic**
24 **protein-3 is a myocardial MSC homing factor.** *Stem Cells* 2007, **25**.
- 25 54. Sharkey J, Scarfe L, Santeramo I, Garcia-Finana M, Park BK, Poptani H, Wilm B, Taylor
26 A, Murray P: **Imaging technologies for monitoring the safety, efficacy and**
27 **mechanisms of action of cell-based regenerative medicine therapies in models of**
28 **kidney disease.** *European Journal of Pharmacology* 2016, **790**:74-82.
- 29 55. Lin P, Correa D, Kean TJ, Awadallah A, Dennis JE, Caplan AI: **Serial Transplantation**
30 **and Long-term Engraftment of Intra-arterially Delivered Clonally Derived**
31 **Mesenchymal Stem Cells to Injured Bone Marrow.** *Molecular Therapy* 2014, **22**:160-
32 168.

- 1 56. Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, von Bonin M,
2 Barbieri L, Halai K, Ward S, et al: **Apoptosis in mesenchymal stromal cells induces in**
3 **vivo recipient-mediated immunomodulation.** *Science Translational Medicine* 2017,
4 **9.**
5
6
7 57. Wang Y, Wang YP, Zheng G, Lee VWS, Ouyang L, Chang DHH, Mahajan D, Coombs J,
8 Wang YM, Alexander SI, Harris DCH: **Ex vivo programmed macrophages ameliorate**
9 **experimental chronic inflammatory renal disease.** *Kidney International* 2007,
10 **72:290-299.**
11
12
13 58. Geng Y, Zhang L, Fu B, Zhang J, Hong Q, Hu J, Li D, Luo C, Cui S, Zhu F, Chen X:
14 **Mesenchymal stem cells ameliorate rhabdomyolysis-induced acute kidney injury**
15 **via the activation of M2 macrophages.** *Stem Cell Res Ther* 2014, **5:80.**
16
17
18 59. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S,
19 Poluektova L, Nelson JA, Chaubal M, et al: **Development of a macrophage-based**
20 **nanoparticle platform for antiretroviral drug delivery.** *Blood* 2006, **108:2827-2835.**
21
22
23 60. Barrett DM, Seif AE, Carpenito C, Strong EP, June CH, Grupp SA, Reid GSD:
24 **Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia**
25 **Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of**
26 **Leukemia.** *Blood* 2010, **116:2140.**
27
28
29 61. Diduch DR, Coe MR, Joyner C, Owen ME, Balian G: **Two cell lines from bone marrow**
30 **that differ in terms of collagen synthesis, osteogenic characteristics, and matrix**
31 **mineralization.** *J Bone Joint Surg Am* 1993, **75:92-105.**
32
33
34 62. Juffroy O, Noel D, Delanoye A, Viltart O, Wolowczuk I, Verwaerde C: **Subcutaneous**
35 **graft of D1 mouse mesenchymal stem cells leads to the formation of a bone-like**
36 **structure.** *Differentiation* 2009, **78:223-231.**
37
38
39 63. Lye KL, Nordin N, Vidyadaran S, Thilakavathy K: **Mesenchymal stem cells: From stem**
40 **cells to sarcomas.** *Cell Biol Int* 2016, **40:610-618.**
41
42
43 64. Mohseny AB, Hogendoorn PC: **Concise review: mesenchymal tumors: when stem**
44 **cells go mad.** *Stem Cells* 2011, **29:397-403.**
45
46
47 65. Karp JM, Leng Teo GS: **Mesenchymal stem cell homing: the devil is in the details.**
48 *Cell Stem Cell* 2009, **4.**
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 66. Xu XC, Goodman J, Sasaki H, Lowell J, Mohanakumar T: **Activation of natural killer**
 2 **cells and macrophages by porcine endothelial cells augments specific T-cell**
 3 **xenoresponse. *Am J Transplant* 2002, 2:314-322.**
 4 67. Barcia RN, Santos JM, Filipe M, Teixeira M, Martins JP, Almeida J, Agua-Doce A,
 5 Almeida SC, Varela A, Pohl S, et al: **What Makes Umbilical Cord Tissue-Derived**
 6 **Mesenchymal Stromal Cells Superior Immunomodulators When Compared to Bone**
 7 **Marrow Derived Mesenchymal Stromal Cells? *Stem Cells Int* 2015, 2015:583984.**
 8 68. Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, Tse HF, Fu QL, Lian Q:
 9 **Mesenchymal stem cells and immunomodulation: current status and future**
 10 **prospects. *Cell Death Dis* 2016, 7:e2062.**

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 **Figure Legends**

32
33
34
35
36
37 **Figure 1. Biodistribution of different cells following intravenous or intracardiac**
 38 **administration. (a)** BLI immediately after administration, showing that cells were always
 39
40 confined within the lungs after intravenous (IV) administration, but distributed throughout
 41
42 20 the body after intracardiac (IC) administration; an exception were the macrophages which
 43
44 21 showed also a more posterior signal after IV administration. The diameter of each cell as
 45
46 22 estimated by the PCV is shown next to the images. *Ex vivo* bioluminescence imaging of
 47
48 23 organs within 1h of administration of **(b)** mKSCs or **(c)** macrophages confirmed the *in vivo*
 49
50 24 cell biodistribution. Organs are indicated as kidneys (k), spleen (s), liver (li), lungs (lu), heart
 51
52 25 (h) or brain (b) and the colour scale applies to both administration routes. Quantification of
 53
54 26 the bioluminescence signal intensity of organs *ex vivo* post **(d)** mKSC or **(e)** macrophage
 55
56
57
58
59
60
61
62
63
64
65

1 administration. Values represent the mean signal intensity measured in each organ and
2 normalised to the total flux from all organs ($n = 3$ each group). Error bars represent standard
3 error. **(f)** Mean pixel intensity of GNR-labelled macrophages measured via multispectral
4 optoacoustic tomography for a period of 5 hours post IV administration, displaying the
5 kinetics of their accumulation in the spleen and liver. Arrow indicates the time point at
6 which the cells were administered.

7
8 **Figure 2. MRI and immunofluorescence images of mMSCs in the brains and kidneys.** *In vivo*
9 and post-mortem T_2^* -weighted images of the **(a)** brains and **(b)** kidneys of mice pre- and
10 post-administration of SPION-labelled mMSCs via the IV or IC route. **(c)** Epifluorescence of
11 ZsGreen (green) and nuclei (blue) of a single kidney glomerulus (top) and the corresponding
12 Prussian Blue image (bottom) demonstrating that cells and SPIONs co-localised to the same
13 spatial location. Scale bars correspond to 10 μm . **(d)** Overlay of confocal microscopy images
14 of Isolectin-IB 4 staining (red), ZsGreen (green) and nuclei (blue). Tissue sections were
15 obtained from the brain (left) or kidney (right) of mice **culled within 5 hours after having**
16 received cells IC.

17
18 **Figure 3. Short-term fate of mMSCs imaged *in vivo* and post-mortem.** **(a)** BLI, MRI (*in vivo*,
19 post-mortem) and fluorescence microscopy images of the kidneys immediately **(on day 0,**
20 **within 5 hours), or on day 1 or day 2** after IC administration of SPION-labelled mMSCs.
21 Fluorescence images were obtained from tissue sections where green fluorescence
22 corresponds to ZsGreen expression and blue fluorescence to DAPI staining. Arrowheads
23 indicate individual glomeruli. Scale bar corresponds to 100 μm . T_2^* relaxation time of **(b)**
24 kidney cortices or **(c)** liver before (baseline) and up to 2 days after cell administration. The

1 T₂* relaxation time in the cortex of the kidney was significantly lower on the day of cell
2 administration (day 0, mean = 7.98 ms +/- SE = 0.29) than at baseline (14.56 +/- 0.32 ms;
3 One-way ANOVA, p < 0.001). The T₂* relaxation time then increased towards baseline levels
4 at day 1 (12.57 +/- 0.50 ms) and day 2 (13.19 +/- 0.23 ms), and by day 2 the difference
5 compared with baseline levels was no longer statistically significant. In the livers, T₂*
6 relaxation time revealed a subtle but significant decrease in relaxation time from baseline to
7 day 2 (baseline, 7.19 +/- 0.29 ms; day 0, 5.48 +/- 0.38 ms; day 1, 5.10 +/- 0.16 ms; day 2, 5.02
8 +/- 0.94 ms; One-way ANOVA, p = 0.006). Time points that do not share the same letters are
9 significantly different from one another, p < 0.05 (Tukey's post hoc test).

10
11 **Figure 4. Impact of administration route on long-term tumour formation. (a)**

12 Representative BLI of SCID mice administered with mMSC via the IC or IV route. BLI scale
13 corresponds to levels between 1.0x10⁵-1.0x10⁶ p/s/cm²/sr. Quantification of the
14 bioluminescence signal from each individual mouse that received mMSCs **(b)** IC (n=5) or **(c)**
15 IV (n=3) up to day 17. Signal corresponds to a region of interest drawn around the whole
16 body of the mouse. **(d)** Mean whole body quantification of the bioluminescence signal up to
17 day 30. Error bars represent SE. **(e)** T₂-weighted MRI of tumours in animals that received
18 mMSCs via IC or IV as imaged 30 days post administration. Arrows indicate individual
19 tumours, usually in the skeletal muscle apart from the IV route, where a tumour was found
20 close to the lungs.

21
22 **Figure 5. Tumour-formation potential in different mouse strains.** Representative BLI of
23 longitudinal tumour monitoring in four strains of mouse following IC administration of
24 mMSCs. **(a)** immunocompromised BALB/c SCID, **(b)** Immunocompetent BALB/c **(c)**, FVB or **(d)**

1 MF1 mice. BALB/c mice showed very similar tumour formation potential to BALB/c SCID
2 mice, with respect to timing, size and location of tumour development. After 21 days, the
3 strong signal originating from the tumours required a colour scale two orders of magnitude
4 greater than that at 0h to accurately display the tumour location. FVB and MF1 mice
5 displayed weaker BLI foci at day 28, and not all animals displayed the same tumour
6 distribution. Balb/c SCID data in **(a)** has been partially reproduced from Fig. 4a to facilitate
7 comparison between strains. **(e)** Mean whole body quantification of the bioluminescence
8 signal up to day 30. Error bars represent SE. **(f)** Photograph of the hindquarters of a Balb/c
9 mouse after removal of the skin. Multiple tumour foci are indicated with arrows,
10 demonstrating their presence in the skeletal muscle close to the femurs, hips, and spine. **(g)**
11 BLI of tumours harvested 30 days post-administration of mMSCs confirming that tumours
12 originated from the administered cells and not host tissue. **(h-k)** Histological examination of
13 tumour tissue. **(h)** H&E staining and corresponding **(i)** epifluorescence imaging of the
14 ZsGreen reporter. Differences in cell composition between the tumour (***) and normal
15 tissue (*) are denoted. Scale bars represent 100 μm . **(j, k)** Higher magnification of tumour
16 tissue showing cancer cells arranged in densely cellular monomorphic areas. Scale bars
17 correspond to 50 μm and arrow indicates mitotic figures, one of which is shown in the inset.
18 **(k)** Corresponds to an area where the tumour is moderately cellular with production of
19 unmineralised osteoid (black arrowhead) and partially mineralised matrix (red arrowhead).
20
21 **Figure 6. Long-term monitoring of human MSCs in Balb/c mice. (a)** Representative BLI of
22 mice administered with 5×10^5 hBM-MSC or hUC-MSC via the IC or IV route. The signal was
23 progressively lost shortly after administration, with no evidence of malignant growth. **(b)** Ex
24 vivo bioluminescence imaging of organs within 5h of administration of the cells. Organs are

1 indicated as kidneys (k), spleen (s), liver (li), lungs (lu), heart (h) or brain (b). In some
 2 occasions signal foci were seen in the heart of mice that received hUC-MSK IV (red arrow).
 3 **(c)** BLI images from mice that displayed hUC-MSK signal that persisted beyond day 7 (ventral
 4 orientation, lower scale). In all cases, the signals had disappeared by day 21 and had not
 5 returned by the end of the experiment.

8 Tables

10 Table 1. Experimental details of studies, mouse strains, cell types, route of administration,
 11 dose and number of animals studied

Study	Mouse strain	Cell Type	Route	Dose	Number of animals
BLI short-term biodistribution (and MSOT for RAW macrophages)	BALB/c	mMSC	IV and IC	1.0 x10 ⁶	Minimum n = 3 for each cell type and administration route
	BALB/c	mKSC	IV and IC	1.0 x10 ⁶	
	BALB/c	hUC-MSK	IV and IC	1.0 x10 ⁶	
	BALB/c	hBM-MSK	IV and IC	5.0 x10 ⁵	
	BALB/c	hKC	IV and IC	0.3 x10 ⁵	
	BALB/c	macrophages	IV and IC	1.0 x10 ⁷	
BLI long-term biodistribution	BALB/c SCID	mMSC	IV	1.0 x10 ⁶	n = 3
	BALB/c SCID	mMSC	IC	1.0 x10 ⁶	n = 5
	BALB/c	mMSC	IC	1.0 x10 ⁶	n = 4
	FVB	mMSC	IC	1.0 x10 ⁶	n = 4

	MF1	mMSC	IC	1.0 x10 ⁶	n = 4
	BALB/c SCID	hUC-MSC	IV	1.0 x10 ⁶	n = 13
	BALB/c SCID	hUC-MSC	IC	1.0 x10 ⁶	n = 3
	BALB/c SCID	hUC-MSC	IV	5.0 x10 ⁵	n = 6
	BALB/c SCID	hUC-MSC	IC	5.0 x10 ⁵	n = 14
	BALB/c SCID	hBM-MSC	IV	5.0 x10 ⁵	n = 6
	BALB/c SCID	hBM-MSC	IC	5.0 x10 ⁵	n = 6
MRI cell	BALB/c	mMSC	IV	1.0 x10 ⁶	n = 2
tracking	BALB/c	mMSC	IC	1.0 x10 ⁶	n = 7

Cell numbers for IC administration had to be individually optimised for each cell type used since mice responded severely to higher numbers of some of the cell types after injection into the left ventricle. Administered cell numbers caused no health problems after IV injection in any of the cell types used.

Additional File Legends

Additional File 1 (pdf). Summary of registered clinical studies involving umbilical cord-derived MSCs.

Additional File 2 (pdf). Culture media used for growing cells.

Additional File 3 (pdf). Detailed method of ultrasound guided intracardiac injection of cells.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Additional File 4 (pdf). MSOT images of GNR-labelled macrophages in different organs.

Snapshot images of the abdomen of mice, showing the **(a)** liver, delineated with red lines and **(b)** kidney, delineated with a yellow line or spleen, delineated with a green line. Images correspond to baseline imaging (pre-administration) and 4h post IV administration of GNR-labelled RAW macrophages. GNR-labelling generates MSOT contrast, seen as an increase in pixel brightness for areas corresponding to liver and spleen. Kinetic imaging over a period of 4h was used to generate data shown in Fig. 1f. **(c)** Quantification of the MSOT mean pixel intensity in the liver, spleen or kidneys 4h post administration of GNR-labelled RAW macrophages IV or IC. Data is displayed as fold changes in pixel intensity in respect to baseline measurements.

Additional File 5 (pdf). Placement of a region of interest (ROI) for the calculation of

relaxation time in the kidney's cortex. (a) In vivo T_2^* -weighted image of a single kidney post administration of SPION-labelled mMSCs, **(b)** placement of an ROI (yellow line) covering the cortex of the kidney where cell/SPION contrast is observed and **(c)** the changes in signal intensity as a function of echo time, with the solid line displaying the exponential fit of the data, from where the relaxation time is derived. Relaxation times were calculated with Paravision 6.0.1.

Additional File 6 (pdf). MRI sequences and acquisition parameters. All *in vivo* data was

acquired with a 4-channel surface coil designed for the mouse brain or abdomen. Post mortem data was obtained with a 27 mm volume coil.

1 **Additional File 7 (pdf). mMSC distribution between day 14 and 30. (a)** From day 24
2 onwards for IC-injected mice, it was necessary to increase the scale by two orders of
3 magnitude (BLI scale $1.0 \times 10^7 - 1.0 \times 10^8$ p/s/cm²/sr, orange frame) compared to that in Fig.
4 4 to enable visualisation of the very strong signals resulting from rapidly proliferating
5 mMSCs. **(b)** Using the original scale (see Fig. 4: $1.0 \times 10^5 - 1.0 \times 10^6$ p/s/cm²/sr), signals could
6 be detected by day 24 in one (out of 3) IV-injected mice. **(c,e)** Representative in vivo and
7 corresponding **(d,f)** ex vivo organ images at day 30. **(d)** Small spots of bioluminescence signal
8 could be detected in some of the organs of IC-injected BALB/c SCID mice (arrows), but the
9 scale had to be lowered to $1.0 \times 10^4 - 1.0 \times 10^5$ p/s/cm²/sr (blue frame) in order to be able to
10 display these weak signals. **(e)** Two out of three IV-administered BALB/c SCID mice did not
11 show any signals at day 30 in vivo using the standard scale (green frame), however,
12 corresponding **(f)** organ imaging showed small foci of bioluminescence signals in the lungs
13 (arrows).

14

15 **Additional File 8 (pdf). Fluorescence Activated Cell Sorting (FACS) analysis of bone marrow**
16 **extracts.** Green fluorescence analysis of cells harvested from the femurs and tibias of **(a)** a
17 control mouse that received no cells **(b)** a mouse that received mMSCs IC display no
18 evidence of ZsGreen+ cells in the bone marrow.


19


20 **Additional File 9 (pdf). Chromosome analysis of the (a) mMSCs, (b) hBM-MSCs and (c) hUC-**
21 **MSCs.** Whereas mMSCs displayed a grossly abnormal karyotype, the human cells displayed a
22 normal female karyotype.




23


1 **Additional File 10 (pdf). Ex vivo imaging of organs immediately after administration of 10^6**


2 **hUC-MSC. (a)** Intracardiac administration always results in BLI signal originating from organs
3 in addition to the lungs. Intravenous administration, on the other hand, leads to cells lodging
4 predominantly in the lungs. For hUC-MSCs, however, a weak signal was seen in heart, which
5 was particularly noticeable when the lungs were removed from the imaging field. BLI scale:
6 all organs $1.0 \times 10^5 - 1.0 \times 10^7$ p/s/cm²/sr, lungs removed: $1.0 \times 10^4 - 4.0 \times 10^5$ p/s/cm²/sr. **(b-c)**
7 Relative bioluminescence intensity in each organ as measured *ex vivo* post **(b)** IC or **(c)** IV
8 administration. The signal intensity of mKSCs as shown in Fig. 1d is displayed as a reference.
9 Note that following IV administration, the sum of the signal in organs other than the lungs is
10 generally less than 2% of the total. A break has been inserted in the y-axis to facilitate the
11 visualisation of the data.
















Click here to access/download
Supplementary Material
AF1.pdf





Click here to access/download
Supplementary Material
AF2.pdf





Click here to access/download
Supplementary Material
AF3.pdf





Click here to access/download
Supplementary Material
AF4.pdf





Click here to access/download
Supplementary Material
AF5.pdf





Click here to access/download
Supplementary Material
AF6.pdf





Click here to access/download
Supplementary Material
AF7.pdf





Click here to access/download
Supplementary Material
AF8.pdf





Click here to access/download
Supplementary Material
AF9.pdf





Click here to access/download
Supplementary Material
AF10.pdf

